Resolution of Eosinophilic Pneumonia after Coronavirus Disease 2019 without Systemic Corticosteroids

Intern Med. 2023 Nov 1;62(21):3223-3230. doi: 10.2169/internalmedicine.1648-23. Epub 2023 Aug 16.

Abstract

Pulmonary and extrapulmonary complications after coronavirus disease 2019 (COVID-19) have been major public health concerns during the COVID-19 pandemic. Although post-COVID-19 pulmonary manifestations cover a wide spectrum, eosinophilic pneumonia (EP) has rarely been reported. To date, only four cases of EP potentially triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported, all of which required systemic corticosteroid therapy. We herein report the first case of post-COVID-19 EP resolution without systemic corticosteroid therapy. We also review the literature regarding EP associated with SARS-CoV-2 infection and vaccination.

Keywords: COVID-19; COVID-19 vaccines; SARS-CoV-2; eosinophilic pneumonia.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • COVID-19*
  • Humans
  • Pandemics
  • Pulmonary Eosinophilia* / drug therapy
  • Pulmonary Eosinophilia* / etiology
  • SARS-CoV-2

Substances

  • Adrenal Cortex Hormones